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Calcium-binding protein in the duodenal mucosa of uremic patients
and normal subjects. In the present study we measured the content
and determined the localization of a calcium-binding protein
(CaBP) in the intestinal biopsy specimen of ten patients with severe
renal insufficiency and in eight healthy individuals. In each patient
a biopsy specimen of the iliac crest was obtained for evaluation of
the degree of osteodystrophy. The CaBP was isolated from human
kidneys. Its identity with human intestinal CaBP was suggested by
acrylamid gel electrophoresis. Specific antibodies against it were
developed in rabbits. The content of CaBP in duodenal mucosa
biopsy material was measured by quantitative radial immunodiffu-
sion. Its mean value in the duodenum of patients with renal insuffi-
ciency was 3.65 1.14 zg; in that of normal persons, 10.80 3.20
sg/mg of protein in the supernatant. There was neither a correla-
tion between the type and duration of renal insufficiency and the
CaBP content of the specimens nor between the degree of renal os-
teodystrophy and CaBP content. In normal persons the specific im-
munohistological activity indicating the presence of CaBP was
found uniformly along the brush border and basement membrane
of the duodenal epithelial and the goblet cells. In uremic patients
the fluorescence was markedly reduced in the typical locations, es-
pecially in the brush border area.
Protéine liant le calcium dans Ia muqueuse duodénale des sujets at-
teints d'urémie et des sujets normaux. Le contenu en protCine liant
Ic calcium (CaBP) et sa localisation ont été déterminés dans les
échantillons de biopsies intestinales de dix malades atteints d'in-
suffisance rénale sévère et de huit sujets normaux. Chez chaque
malade un échantillon biopsique de crete iliaque a etC prélevC afin
d'apprécier Ic degré d'ostCodystrophie. CaBP a été isolé a partir de
reins humains. Son identitC avec Ic CaBP humain intestinal est sug-
gérée par l'électrophorèse en gel d'acrylamide. Des anticorps spé-
cifiques ont été induits chez des lapins. Le contenu en CaBP des
échantillons biopsiques de muqueuse duodCnale a etC mesuré par
immunodiffusion radiale quantitative. La concentration moyenne
dans le duodenum des malades atteints d'insuffisance rénale est de
3,65 1,14 zg et chez les sujets normaux de 10,8 3,20 .sg par mg
de protCines dans Ic surnageant. II n'y a de correlation ni entre Ic
type ou Ia durée de l'insuffisance rénale et Ic contenu en CaBP, ni
entre Ic degrC d'ostéodystrophie et Ic contenu en CaRP. Chez les
sujets normaux I'activitC immunohistologique specifique indiquant
Ia presence de CaBP existe uniformément Ic long de Ia bordure en
brosse et de Ia membrane basale des cellules épithCliales et
caliciformes du duodenum. Chez les malades atteints d'urémie Ia
fluorescence est nettement réduite, particuliCrement dans Ia region
de Ia bordure en brosse.
Calcium transport across the mucosal cell is greatly
enhanced by calciferol [1]. The discovery of a specific
calcium-binding protein (CaBP) in the intestinal
mucosa of various animal species [2—5], of a Ca-
stimulated adenosine triphosphatase (ATPase)
system [6] and of an alkaline phosphatase in the
brush border of intestinal epithelium, which is pos-
sibly identical with the Ca-ATPase [7], has led to a
better understanding of mechanisms involved in
vitamin D3-dependent calcium absorption by the gut.
Vitamin D3 has been found to be the most important
single component that regulates intestinal calcium
absorption. To be active, vitamin D3 is converted in
the liver to 25-hydroxycholecalciferol (25-OHD3) and
subsequently in the kidney to 1,25-dihydroxychole-
calciferol (l,25(OH)2D3) [8—10].
In uremic patients intestinal calcium uptake is
diminished [11, 12], but it can be restored to normal
by administration of small amounts of l,25(OH)2D3
[13]. This observation and the direct and indirect
evidence that anephric patients and animals fail to
produce l,25(OH)2D3 [8, 14, 15] point to a disturb-
ance of vitamin D metabolism in uremia. Diminished
quantities of CaBP have been reported in the in-
testine of rats with chronic renal failure [16]. In
patients with chronic uremia, we found decreased
amounts of CaBP in duodenal and jejunal tissue after
partially purifying the CaBP and measuring the
calcium-binding capacity by the Chelex-lOO test [17].
In the present study, we measured by immunological
techniques the content and determined the localiza-
tion of CaBP in intestinal biopsy specimens of
patients with terminal renal insufficiency and com-
pared these findings to those in healthy individuals.
Methods
Received for publication May 17, 1974;
and in revised form March 31, 1975.
© 1975, by the International Society of Nephrology.
110
Laboratory methods. By heating, centrifugation,
repeated gel filtration and ion exchange chro-
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matography of histological normal renal tissue, a
purified human CaBP was obtained [18]. For im-
munological purposes we purified this protein further
by rechromatography on DEAE-cellulose using in-
creasing concentrations of NaC1 (0,05 to 2.0 M) and
0.01 M Tris-HCI buffer, pH 7.4 (column, 40 X 2.5
cm; elution fate, 60 ml/hr; fractionation, 3 mI/tube).
The eluted protein fractions were dialyzed against
distilled water, lyophylized and tested for calcium-
binding ability by the Chelex-100 method [18, 19].
Protein concentration in column eluates was
measured as absorbance at 280 nm. In quantitative
studies of binding, protein was measured by the
method of Lowry et al [20]. The eluted protein frac-
tion with calcium-binding ability was tested for its
purity on polyacryl'amid gel electrophoresis accord-
ing to the method of Davis [21].
A specific antiserum against the highly purified
CaBP was prepared by injection in New Zealand rab-
bits. Three mg of the CaBP was dissolved in 2 ml of
saline solution and emulsified in 2 ml of complete
Freunds Adjuvant (Difco Lab., Detroit, MI, U.S.A.).
Animals were given 0.2 ml of the solution in-
tracutaneously between the toes, and subcutaneously
into the skin of the neck, at two-week intervals for 8
to 12 weeks. The animals were bled, and gamma
globulin was extracted from the serum by Sephadex
G-75 filtration for use in the immunological
procedures. Specificity of antiserum and im-
munochemical identity of antigens in tissue super-
nates were assessed by Ouchterlony's technique of
double immunodiffusion [22]. The concentration of
CaBP in tissue supernates was measured by the
method of Mancini, Carbonara and Heremans using
quantitative radial immunodiffusion [231.
Immediately following the intestinal biopsies, one
part of the specimen was placed in electrophoresis
buffer (buffer composition: 19.6 18 g of diethylsodium
barbiturate, 12.952 g of sodium acetate, 180 ml of 0.1
N HC1, distilled water to 2,000 ml; adjusted to pH 8.6
with either 0.1 N HC1 or 0.1 N NaOH), ultrasonically
homogenized (Biosonik III, Bronwill Sci.) and
centrifuged at 36,000 X g. To calculate the specific ac-
tivities of the CaBP, the protein content of the super-
natant was measured according to the procedure of
Lowry et al [20] after concentration of the superna-
tant tenfold using a cellophane tube and carbowax
(C. Roth OHG, Karisruhe, Germany). The agar
plates containing antiserum were prepared using a
1: 1 mixture of antiserum diluted 1: 10 to 1: 100 in
the above-mentioned electrophoresis buffer and 3%
agar electrophoresis buffer, after warming the mix-
ture to 60°C. This antiserum-agar gel mixture was
poured on a thermostatically warmed glass slide (7.5
X 2.5 cm). The thickness of the layer was 1.0 mm.
Five to 15 tl of the antigen-containing material was
instilled into the punched holes of the plates
(diameter, 2.2 to 4.2 mm). After incubation for 24 to
36 hr in a wet chamber at 37°C, the precipitation
rings were completely developed. The external
diameter of the rings was measured and related to
standard antigen solution of purified human CaBP of
different concentrations. The site of CaBP in the in-
testinal mucosa was estimated by indirect fluores-
cence [24]. Immediately after the duodenal biopsy
was obtained, a part of the specimen was rapidly
frozen and cut by a cryostat microtome at —27°C.
The 4 to 6 thick sections were placed on a cold glass
slide and briefly thawed (2 to 4 sec) in order to allow
the section to adhere to the slide. The sections were
then overlaid with the CaBP-specific rabbit gamma
globulins for 30 mm and washed three times for 5 mm
each with phosphate-buffered saline. Subsequently,
the slide was layered with goat-antirabbit gamma
globulin (20 mm) conjugated with fluoresciniso-
thiocyanate (Behring Werke, Marburg, Germany)
which had been purified by DEAE 50 chroma-
tography and dissolved in phosphate buffer 1: 10.
The sections were washed with buffered saline
(15 mm), covered with phosphate-buffered glycerol
and evaluated by means of a fluorescence microscope
(Zeiss) equipped with a 200-watt high pressure mer-
cury vapor lamp (Osram HBO) and B 6-6 and
64/470 mt filters (Zeiss, Oberkochen, Germany). To
exclude nonspecific immunological activity, sections
of the same tissue block were layered and incubated
with either nonspecific gamma globulin or CaBP-
adsorbed specific rabbit gamma globulins. Addi-
tional sections of each biopsy specimen were stained
with hematoxylin-eosin and examined under bright
field illumination.
Serum concentrations of urea, creatinine, calcium,
phosphorus and alkaline phosphatase were measured
using standardized routine methods. The normal
range of alkaline phosphatase is 6 to 31 mU/liter.
Patients. The investigations were performed on
nine patients with chronic glomerulonephritis in
renal failure, one patient with rapidly progressive
glomerulonephritis in renal failure (Table 1) and
eight subjects without signs of renal or gas-
trointestinal disorders. The mean age in the uremic
group was 43 yr, and in the control group, 39 yr.
Seven were women and 11 were men. The control
group consisted of eight hospitalized patients in very
good general condition but suffering from functional
gastrointestinal complaints which were examined by
gastroduodenoscopy. These persons did not receive
any medication except antacids or spasmolytic drugs.
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Table 1. Clinical features, status of renal function, results of bone biopsies and CaBP content of duodenal biopsy specimens from ten
uremic patientsa
Serum Serum Serum Serum Iliac crest bone
creati- Serum cal- phos- alk phos- biopsy CaBP
nine urea cium phorus phatase content
Patient Age mg/ mg/ mEq/ mgi mgi Osteo- Osteitis ,2g/mg of
No. Sex yr Diagnosis 100 ml 100 ml liter 100 ml 100 ml malacia fibrosa protein
1 F 60 Chron PN 13.8 218 3.1 6.4 27 + 0 3.1
2 F 46 Chron PN 11.2 252 3.0 5.3 38 + + + 3.4
3 M 38 Chron PN 17.7 208 3.6 5.9 22 ++ + 3.6
4 M 62 NL 10.2 345 2.9 7.4 35 + + 3.5
5 F 30 Chron GN 22.7 173 3.4 6.4 16 + + 3.0
6 M 33 Chron ON 11.6 127 3.2 5.0 16 + + 4.8
7 F 52 Chron ON 10.2 197 3.9 8.2 53 +++ (+) 2.7
8 M 48 Chron ON 10.4 185 3.3 7.2 28 ++ + 4.2
9 F 35 Chron ON 12.4 157 4.0 6.1 21 ++ (+) 5.0
10 M 29 Rapidly
progr GNb
10.2 230 4.8 6.2 8 0 (+) 3.2
sThe glomerular filtration rate of all patients was less than 6 mI/mm. PN = pyelonephritis, NL = nephrolithiasis, ON = glomerulo-
nephritis.
bBone biopsy four weeks after onset of disease.
All investigated subjects were fully informed of the
planned examination and gave their consent prior to
intestinal biopsy. The nature of the renal disease was
determined by renal biopsy in each case. In each
uremic patient, biopsy of the iliac crest bone was ob-
tained to evaluate the degree of osteodystrophy,
utilizing a micromorphometric method after
methacrylate embedding of the undecalcified bone
specimen [25, 26].
At the time of investigation, two patients were
receiving a potato-egg diet (20 g of protein/day); all
other patients were receiving a diet containing 1 g of
protein/kg of body wt. Aluminium hydroxide gel
(Aludrox) was administered to all patients to prevent
hyperphosphatemia. None of the patients was receiv-
ing vitamin D preparations or calcium supplements.
Six patients had been receiving intermittent
hemodialysis for less than four weeks and two
patients had been on dialysis for four and six months,
respectively. Two patients did not require dialysis.
Intestinal biopsy specimens were obtained with the
aid of a Watson biopsy capsule (Auklin, Basel,
Switzerland). The biopsy site was the horizontal part
of the duodenum, located with the aid of direct
fluoroscopic control. The patients had fasted over-
night prior to the procedure. The wet weight of the
duodenal specimens ranged between 30.5 and 100.8
mg. These quantities are sufficient for determination
of the amount of CaBP and performance of im-
munohistologic studies.
Results
As reported in 1971 [18], we were able to isolate a
protein with strong calcium-binding ability from
human kidney material, which was eluted on DEAE-
cellulose with 0.05 M tris buffer, pH 7.0, containing
0.25 M NaC1. This peak was rechromatographed on
DEAE-cellulose with slightly changed elution buffer
as described in Methods. In Fig. 1 it can be seen that
there is a significant peak of radioactivity associated
with a sharp protein peak eluted with 0.25 M NaC1.
This peak was subjected to polyacrylamide gel
electrophoresis and showed a well-defined double
band, with fast migration towards the anode at pH 9
as shown in Fig. 2. The meaning of the constant ap-
pearance of the double protein band is not clear.
The antiserum produced in rabbits was used in the
development of a quantitative assay for CaBP,
employing the technique of Mancini et al [23] (see
Methods). As shown in Fig. 3, the procedure was
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Fig. 1. Rechromatography of prepurfied kidney calcium-binding
protein on DEAE-cellulose. Elution with 0.O1M Tris buffer, pH 7.4,
with NaCI at concentrations marked in the figure. Elution rate:
60 ml (= 20 fractions)/hr. The absorbance at 280 nmoles (solid
line) was determined on successive fractions eluted from column.
Calcium-binding ability was tested by the Chelex-100 test in every
fraction and was found only in the tubes 115 to 130 as indicated
by the dotted line.
Fig. 2. A crylamide gel electrophoresis at
pH 9.0 (Tris/HCI buffer) of 200 g of
pure human kidney CaBP. Six mAmps,
170 v for two hours. Migration was to-
ward the anode (bottom).
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highly reproducible and permitted an accurate quan-
titation of as little as 1.0 to 1.25 tg of CaBP. With
this assay, therefore, it was possible to measure CaBP
concentration in tissue.
The clinical features and renal function of the
patients and the results of the bone biopsies are given
in Table 1. Serum creatinine and urea concentrations
were markedly elevated; the glomerular filtration rate
was less than 6 mI/mm in all patients. The serum
calcium concentration was depressed markedly in all
patients with the exception of the patient with rapidly
progressive glomerulonephritis. Alkaline phospha-
tase was slightly elevated in three cases and in the
upper range of normal in two cases. Bone biopsy
specimens showed pronounced osteomalacia in com-
bination with minor changes of osteitis fibrosa in
most instances. In the patient with rapidly progres-
sive glomerulonephritis, there was no evidence of os-
teomalacia and minimal signs of osteitis fibrosa. The
hematoxylin—eosin—stained sections of duodenal
biopsies were normal in patients with renal failure
and in control subjects.
The values of the CaBP content of the specimens
are shown in Fig. 4. In the eight healthy subjects, the
content of CaBP was 10.80 3.20 tg/mg of protein
in the 36,000 >< g supernatant of the biopsy material.
There was a marked reduction of CaBP in uremic
duodenal tissue with a mean value of 3.65 1.14
pg/mg of protein, a reduction of 67%. As the number
of investigated patients was small, the type and dura-
tion of renal insufficiency or the degree of renal os-
teodystrophy could not be correlated to the CaBP
content of the intestinal tissue.
Sections of duodenal tissue were exposed to the
gamma globulin fraction of kidney CaBP-specific
rabbit antiserum and then to fluorescinisothiocya-
nate-conjugated goat-antirabbit gamma globulin in
the indirect fluorescent antibody method (Fig.
5). In control subjects, the specific immuno-
logical activity indicated that CaBP was distrib-
uted uniformly along the brush border and the
basement membrane of the epithelial cells, and
around and inside the goblet cells (Fig. 5, a and b).
Immunologic controls consisted of sections from the
same source exposed to specific gamma globulin ab-
sorbed with purified CaBP, which was substituted in
place of specific gamma globulin. These slides and
also the sections treated only with control rabbit
gamma globulin exhibited nonspecific fluorescence as
shown in Fig. 5, c and d. In biopsy specimens from
the uremic patients, CaBP was localized inhomo-
geneously in the brush border area, in the goblet
cells and intensively along the basement membrane.
However, in comparison to the intact intestine of
control subjects, the fluorescence was markedly
reduced or absent in the intestinal brush border area
of the uremic duodenum (Fig. 5, e and fl. The reduc-
tion was significantly less prominent along the base-
ment membrane. The fluorescence of the goblet cells
varied; there was no goblet cell staining in six
patients, while four uremic patients showed strong
fluorescence. The sections of these four uremic
Fig. 3. Quantitative radial immunodiffusion assay for human kidney
CaBP. Employing the method of Mancini et al [23], standard
purified CaBP was used to determine the reproducibility of the
assay. Indicated data points represent mean SEM for three deter-
minations.
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Fig. 4. Content of CaBP in duodenal biopsy material of ten pa-
tients with terminal renal failure (right) in comparison to eight
subjects without renal or gastrointestinal diseases.
patients also showed goblet cell fluorescence in im-
munological control staining with specific gamma
globulin absorbed with purified CaBP.
Discussion
The first part of the discussion is intended to sum-
marize the evidence that our antiserum actually
reacts with vitamin D-dependent intestinal CaBP.
The present study confirms and extends earlier
evidence for the existence of a human CaBP in renal
and duodenal tissue [18]. Besides the vitamin D-
dependent CaBP in chicks, which has been inten-
sively investigated by Wasserman and Taylor [2, 3,
27, 28], a similar protein has been reported in rat [29,
45], dog [30], monkey [4], pig [46] and cow [47] in-
testine. So far only the chick CaBP has been proved
to be present in the small intestine and in the kidney
[28]. Nevertheless, immunologic cross-reactivity has
been observed between bovine intestinal CaBP and
bovine kidney homogenates [47], and CaBP has been
shown to be present in porcine kidney material
(Hitchman AJW, personal communication). Since
our first report about human renal CaBP [31], other
investigators have been able to detect human proteins
with calcium-binding ability [32—35]. As in rat in-
testinal mucosa [37, 38, 45], in bovine [47] and por-
cine [46] small bowel mucosa and in the intestines of
chick, guinea pig and pig [ref. in 47], at least two pro-
teins with calcium-binding ability have been found in
human small intestine. Thus, the preliminary data of
Menczel et al [32] suggest two calcium-binding pro-
teins in human mucosa, with the greatest activity in
the duodenum. Alpers, Lee and Avioli [33] have iden-
tified two proteins with calcium-binding ability in
human small intestine, one of these migrating rapidly
during electrophoresis and having a mol wt of about
20,000 as determined by Sephadex chromatography.
By means of gel filtration of homogenized duodenal
mucosa, we isolated a protein with calcium binding
ability; but further purification of duodenal tissue
could not be done because sufficient material was not
available. As we found calcium-binding activity in
human kidney—and enough of this material was
available to us—we, therefore, undertook the isola-
tion of CaBP from this organ. By gel and ion ex-
change chromatography, we could isolate this protein
in high purity. According to gel chromatographic
pattern, the mol wt of human renal CaBP is in the
range of 24,000 to 28,000 [18]. Our results have been
confirmed recently by Morrissey and Rath [35], who
purified CaBP from human renal necropsy specimens
with a mol wt of 27,000. However, the human in-
testinal CaBP reported by Hitchman and Harrison
[34] was only 12,000 to 13,000 mol wt, Morrissey and
Rath [35] discussed another human renal CaBP with
a mol wt above 70,000. A similar protein with calcium
binding ability was recently reported by Lindgärde
et al [38]. These authors found this protein in con-
centrated normal human urine. The meaning of the
existence of two or three CaBPs in man is still un-
known. However, Fulimer and Wasserman [47] have
demonstrated convincingly three separate CaBPs in
bovine intestine, which possess high affinities for
calcium, exhibit rapid electrophoretic migration rates
on acrylamide gels and have been shown to cross-
react with each other immunologically. These three
components of bovine vitamin D3-dependent CaBP
are interpreted as degradation products of one of
them; but all three were serologically identical in the
immunoassay system developed by Fulimer and Was-
serman. Using this system CaBP could also be
detected in bovine renal tissue [47]. In 1973, one of us
(P. Piazolo) [48] obtained similar results to the
above-mentioned studies with human CaBP; these
findings suggest that human renal CaBP is also
broken down into at least two components. This
could be an explanation for the appearance of two
protein bands of purified human CaBP rapidly mi-
grating towards the anode in acrylamide gel elec-
trophoresis. The disc electrophoretic pattern of the
calcium-binding fraction of human duodenal and
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Fig. 5. Localization of CaBP in frozen sections of duodenal biopsy material by the indirect method. Sections were reacted with CaBP-
specific gamma globulin (A,B,E,F) or CaBP-adsorbed specific gamma globulin (C) or nonspecific gamma globulin (D) followed by
washing and treatment with goat-antirabbit gamma globulin conjugated with fluoresceinisothiocyanate. A—B) In sections from subjects
without gastrointestinal or renal diseases, specific fluorescence can be seen in the brush border area, near the basement membrane of
the intestinal cells and around and inside the goblet cells (A, X 150; B, X650). C—D) Only nonspecific background fluorescence is noted
in the control sections stained with nonspecific gamma globulin (D) and in the immunologically blocked sections of a normal person
(C) (X 150). E—F) In the duodenal tissue section of the uremic patient 7 (see Table 1), no specific fluorescence can be seen in the brush border
area and the goblet cells. The fluorescence of the basement membrane is not diminished (E, x ISO; F, x350).
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renal tissue demonstrates the same protein band
rapidly migrating to the anode at pH 9 [18]. This
band represents the purified human CaBP in kidney
and small intestine of humans. This CaBP was
used to immunize rabbits to produce specific anti-
bodies. Using the technique of Ouchterlony [22], the
presence of CaBP in different tissues was examined
and found only in kidney and small intestine, but
not in stomach, rectum, liver or serum. These
findings correspond to the tissue distribution of
vitamin D-dependent CaBP in chicks [28]. As
recently reported [49] we have demonstrated the
vitamin D-inducibility of human intestinal CaBP. In
collaboration with Dr. J. Ströder and Dr. R. Jeschke,
Children's Hospital of the University of Würzburg,
West Germany, we determined the CaBP content in
duodenal biopsy material from four rachitic children
before and after treatment with vitamin D3 or 25-
hydroxycholecalciferol or both. After treatment there
was a significant (P < 0.01) rise of CaBP content in
the duodenum of the children. These results were
confirmed by the indirect immunofluorescence of that
biopsy material, which showed a marked increase of
specific fluorescence in the apical part of the mucosal
cells [50].
With the technique of Mancini et al [23], the con-
tent of human CaBP in duodenal biopsy material was
determined. The content of CaBP in the duodenal tis-
sue of eight subjects without renal or intestinal dis-
eases is 10.80 3.20 pg/mg of protein of superna-
tant. The scattering of the values is probably due to
different biopsy sites. Taylor and Wasserman [28]
reported a content of vitamin D3-inducible CaBP in
chick intestinal mucosa in the same range of
magnitude. The results of the present study
demonstrate a statistically significant reduction of
immunologically determined CaBP in the duodenal
biopsy specimens of uremic patients to values ap-
proximately one-third of normal. These results cor-
relate well with the data of two uremic patients
reported earlier [17]. In this study the CaBP content
of uremic duodenal mucosa was about one-third less
than the corresponding tissue of patients without
renal disease. The patients suffering from terminal
renal insufficiency of different etiologies and dura-
tions showed in bone biopsy specimens a renal os-
teodystrophy of varying severity. However, there was
no correlation between the duodenal content of
CaBP and the etiology or duration of the disease, or
between the CaBP content and the severity of Os-
teodystrophy. In one patient, with rapidly progres-
sive glomerulonephritis of only four weeks' duration,
there was little or no osteodystrophy, but the content
of CaBP in the duodenal mucosa was reduced to
about the same degree as in patients with long-stand-
ing renal insufficiency. These observation suggest that
the extent of the reduction of CaBP does not depend
on the duration of renal insufficiency. Whether it de-
pends on the severity of the renal failure cannot be
concluded from this study, because all patients had
rates of creatinineclearance of less than 6 mI/mm. In
chronically uremic rats with bone lesions similar to
those in man, Avioli et al [16] found the duodenal
content of CaBP to be reduced, and correlated this
abnormality with a decrease in absorption of calcium
in these animals. The impaired calcium absorption in
nephrectomized rats was markedly improved when
the animals were given small amounts of
l,25(OH)2D3 [39, 40]. Similar results have been
observed in uremic patients by Brickman, Coburn
and Norman [13]. These observations and direct and
indirect evidence for disturbance in the production of
1,25(OH)2D3 in anephric patients or animals [8, 14,
15] point to a disturbance of vitamin D metabolism
in uremia. McGregor, Hamilton and Cohn [5] and
Taylor and Wasserman [27, 41] reported that CaBP is
synthetisized in the intestinal mucosa following the
administration of vitamin D and suggested that the
movement of calcium ions across the intestinal
mucosa would partly depend on the amount of CaBP
in the intestine. Keeping in mind that in uremia
calcium absorption is reduced [11, 12] and the con-
tent of CaBP is distinctly diminished (this report),
one could conclude that both these facts are caused
by the defective vitamin D metabolism in uremia.
Human CaBP has certain characteristics in common
with protein from chick and rat intestine: it has a
similar tissue distribution, similar electrophoretic
mobility, similar molecular weight, similar amount of
content in the well-nourished state and shows a
strong calcium-binding ability. Thus, the reduction of
CaBP in the intestinal mucosa of uremic patients
could be the result of an impaired activation of
vitamin D3 in the damaged kidneys. Direct proof of
this hypothesis will be gained by measurement of in-
testinal CaBP in l,25(OH)2D3-treated uremic
patients, an investigation which is planned by us.
Using the fluorescent-labelled antibody technique,
we were able to investigate the localization of the
CaBP in the duodenal mucosa in normal subjects and
in uremic patients. Unspecific fluorescence could be
excluded by two facts: specific fluorescence disap-
peared when the antiserum was pretreated with
purified CaBP, and exposure to serum of nonim-
munized rabbits did not show any specific activity.
Taylor and Wasserman [42] reported that CaBP is
found only in the brush border area and the goblet
cells in the intestinal mucosa of vitamin D3-treated
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rachitic chicks. They assumed that the "functional"
CaBP is that which is present along the brush border
in the surface coat-microvillar region of the intestinal
epithelial cells, and that the goblet cells represent the
place of synthesis of CaBP. In patients with uremia
intestinal tissue gave a quantitative pattern of im-
munofluorescence to an antibody to renal CaBP that
was significantly less than that observed in
presumably healthy individuals. If, as we believe to
be true, the immunofluorescence reaction reflects a
measurement of intestinal CaBP, it would indicate
that there is a quantitative reduction of intestinal
CaBP in patients with uremia. This observation is
consistent with those of others in which an impair-
ment of intestinal calcium absorption has been
described in such patients.
As the calcium-dependent ATPase system is also
induced by vitamin D [6, 7], CaBP is only one factor
in the calcium absorption-facilitating process induced
by vitamin D. On the other hand, uremia per se could
reduce the intestinal response to 1,25(OH)2D3 [40] or,
as suggested by Avioli [43], could induce specific
derangements in the metabolism of the intestinal cell.
Shear [44] has revealed possible defects of the in-
testinal protein synthesis caused by one or more
retained uremic toxins; the diminished content of
CaBP in uremic duodenal mucosa could be the result
of a defective synthesis of this protein. The fact that
more questions can be asked than answered illus-
trates that much more work has still to be done to
gain better understanding of the mechanisms under-
lying the defective intestinal absorption of calcium in
uremia.
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